Compare Newmont Corporation (NEM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs TG Therapeutics Inc — how do they compare? Newmont Corporation trades at $117.84 (market cap $121.75B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Newmont Corporation is far larger — about 14.9× TG Therapeutics Inc's market cap, and Newmont Corporation pays a 0.9% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 58 Days and TG Therapeutics Inc for 16 Days on average.
| NEM | TGTX | |
|---|---|---|
Market Cap | $121.75B | $8.16B |
Volume | 5,421,125 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $59.06 |
52-Week Low | $78.63 | $26.94 |
Typical Hold Time | 58 Days | 16 Days |
Enterprise Value | $118.34B | $8.37B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $117.84, up 3.79% over the past 24 hours, with a bearish technical signal but strong fundamental performance. The company reported record free cash flow of $5.3 billion in H1 2026 and has consistently beaten earnings estimates in recent quarters. Revenue grew to $22.67 billion in 2025, with net income reaching $7.09 billion, reflecting a robust profit margin of 31.25%.
The outlook remains positive due to strong cash flow generation and operational improvements, though near-term technical weakness and gold price volatility present risks. Analyst consensus is strongly bullish with a $136.83 price target, indicating potential upside. Key risks include dependence on gold prices and execution of growth projects.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
